Rapid-Turnaround Co-Administration of mRNA-Based MHC-I and MHC-II-Restricted Neoantigens Enhances Immune Responses of Antigen-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells and Anti-Cancer Efficacy in Colorectal Cancer. This evidence concerns the gene CD8A and cancer.